Screener Summaries Updates Institutions Sign In More Updates › Leadership & Pay › LGVN Leadership & Pay · Nov 5, 2026
Longeveron director Ursula Ungaro resigns from board and all committees LGVN Longeveron Inc.
On November 1, 2026, Ms. Ursula Ungaro resigned immediately from Longeveron Inc.'s Board of Directors and its Audit, Compensation, Nominating and Corporate Governance, and Special Committees. She cited personal health issues as the reason for her departure, stating there was no disagreement with the company regarding operations or policies. Longeveron operates in the cell therapy industry.
More from Longeveron Inc. Longeveron reports laromestrocel reduced MACE by 87% in HLHS Phase 2b trial, plans FDA meeting Oct 26, 2026 Longeveron CMO Nataliya Agafonova steps down effective Oct. 14 Oct 14, 2026 On September 16, 2026, Longeveron Inc. announced that its Phase 2b ELPIS II clinical trial for laromestrocel in… Sep 23, 2026 Longeveron Inc. announced the effective date for its previously approved one-for-ten reverse stock split of Class A… Aug 24, 2026 Longeveron Inc. appointed Nirav S. Jhaveri as Chief Financial Officer, principal financial officer, and principal… Aug 19, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
